Zivcić-Cosić Stela, Vlahović Ana, Grzetić Mirjana, Matić-Glazar Durdica
Odjel za nefrologiju i dijalizu, Klinika za internu medicinu, Klinicki bolnicki centar Rijeka, Medicinski fakultet u Rijeci, Rijeka, Hrvatska.
Acta Med Croatica. 2004;58(3):215-20.
The dialysis population is steadily rising as a consequence of the growing incidence of terminal renal failure patients and lack of organs for transplantation. Peritoneal dialysis (PD) has become an established form of renal replacement therapy. The development of new methods, techniques, PD fluids and catheters has significantly lowered the incidence of complications and increased the use of PD throughout the world. The development of PD at Rijeka University Hospital Center, the incidence of PD patients, their underlying renal disease leading to terminal renal failure, demographic characteristics of patients, complications of treatment, and causes of discontinuation of PD treatment are described. At Rijeka University Hospital Center, PD was introduced in 1963 in patients with acute renal failure (ARF), and in 1965 in patients with chronic renal failure (CRF). Until June 2002, 149 patients were treated, 71 with ARF and 78 with CRF. Continuous peritoneal dialysis was introduced at our hospital in 1978. An increasing number of patients on continuous ambulatory peritoneal dialysis (CAPD), altogether 35, was noticed in 1999. Automated peritoneal dialysis (APD) was introduced in January 2001. Five patients were treated with this method until June 2002. The most common underlying renal diseases in patients treated from January 1999 until June 2002 were diabetic nephropathy in 13 (37.1%) and glomerulonephritis in 11 (31.4%) patients, mean age 55.5 years, range 31-75 years, both sexes equally present. The leading cause of complications were infections and the main cause of death was cardiovascular disease. Five (14.3%) patients received kidney transplants which have been functioning well in all of them. Because of the high incidence of complications during the seventies, intermittent peritoneal dialysis (IPD) was used only occasionally. A significant increase in the number of patients on CAPD was observed in 1999. By the end of 2001 almost ten percent of patients receiving dialytic treatment were on CAPD. The most common complications were peritoneal catheter exit site infection and peritonitis, which caused referral to HD treatment in four (11.4%) and death in two (5.7%) patients with impossible vascular access. The knowledge and availability of different renal replacement therapies allow the choice and application of the most appropriate treatment option in individual patients with terminal renal failure. In comparison to HD, PD improves the quality of patient's life and decreases mortality in the first years of treatment. Patients with cardiovascular disease and diabetes, whose incidence is steadily rising, have a higher incidence of complications on hemodialysis treatment. In these patients PD is preferred, especially if used as the first dialytic treatment modality. PD has also provided a means of managing patients with no possibility for vascular access for HD treatment. Infective and mechanical complications are the main obstacles during PD treatment. Adequate facilities, equipment, educated and well-trained medical personnel and appropriate selection and thorough education of patients are necessary for a successful PD program.
由于终末期肾衰竭患者发病率不断上升以及缺乏可供移植的器官,透析人群正在稳步增加。腹膜透析(PD)已成为一种成熟的肾脏替代治疗方式。新方法、技术、腹膜透析液和导管的发展显著降低了并发症的发生率,并增加了腹膜透析在全球的应用。本文描述了里耶卡大学医院中心腹膜透析的发展情况、腹膜透析患者的发病率、导致终末期肾衰竭的潜在肾脏疾病、患者的人口统计学特征、治疗并发症以及腹膜透析治疗中断的原因。在里耶卡大学医院中心,1963年开始对急性肾衰竭(ARF)患者进行腹膜透析,1965年开始对慢性肾衰竭(CRF)患者进行腹膜透析。截至2002年6月,共治疗了149例患者,其中71例为急性肾衰竭,78例为慢性肾衰竭。1978年我院引入了持续腹膜透析。1999年注意到持续非卧床腹膜透析(CAPD)患者数量不断增加,共有35例。2001年1月引入了自动化腹膜透析(APD)。截至2002年6月,有5例患者采用这种方法进行治疗。1999年1月至2002年6月接受治疗的患者中,最常见的潜在肾脏疾病是糖尿病肾病,共13例(37.1%),肾小球肾炎11例(31.4%),平均年龄55.5岁,年龄范围31 - 75岁,男女比例相同。并发症的主要原因是感染,死亡的主要原因是心血管疾病。5例(14.3%)患者接受了肾移植,所有移植肾均功能良好。由于七十年代并发症发生率较高,间歇性腹膜透析(IPD)仅偶尔使用。1999年观察到CAPD患者数量显著增加。到2001年底,接受透析治疗的患者中近10%采用CAPD。最常见的并发症是腹膜导管出口处感染和腹膜炎,4例(11.4%)患者因这些并发症转为血液透析(HD)治疗,2例(5.7%)血管通路无法建立的患者因这些并发症死亡。不同肾脏替代治疗方法所具备的知识和可及性使得能够为终末期肾衰竭的个体患者选择并应用最合适的治疗方案。与血液透析相比,腹膜透析在治疗的最初几年提高了患者的生活质量并降低了死亡率。心血管疾病和糖尿病患者的发病率在稳步上升,他们在血液透析治疗中并发症的发生率更高。在这些患者中,腹膜透析是首选,尤其是作为首次透析治疗方式时。腹膜透析还为无法进行血液透析血管通路建立的患者提供了一种治疗手段。感染性和机械性并发症是腹膜透析治疗过程中的主要障碍。成功开展腹膜透析项目需要充足的设施、设备、受过教育且训练有素的医务人员,以及对患者进行恰当的选择和全面的教育。